NCT01667731 - Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

February 28, 2014

Conditions

Hepatitis CHuman Immunodeficiency Virus

Interventions

DRUG

SOF

Sofosbuvir (SOF) 400 mg tablet administered orally once daily

DRUG

RBV

Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (27)

Unknown

Birmingham

Coronado

Los Angeles

Lutherville

Oakland

Sacramento

San Francisco

Torrance

Washington D.C.

Miami

Orlando

Tampa

Chicago

Springfield

Kansas City

Hillsborough

Santa Fe

New York

Chapel Hill

Durham

Allentown

Philadelphia

Providence

Dallas

Houston

Seattle

San Juan